Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.

Edesa Biotech Inc has a consensus price target of $27.67 based on the ratings of 3 analysts. The high is $57 issued by Brookline Capital on October 12, 2023. The low is $5 issued by HC Wainwright & Co. on November 3, 2025. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on November 3, 2025, June 27, 2025, and March 13, 2025, respectively. With an average price target of $10.33 between HC Wainwright & Co., there's an implied 598.20% upside for Edesa Biotech Inc from these most-recent analyst ratings.
1calculated from analyst ratings
| Get Alert | |||||
|---|---|---|---|---|---|
| Nov 3, 2025 | 237.84% | 55 | Previous Buy Current Buy | Get Alert | |
| Jun 27, 2025 | 237.84% | 5 | Previous Current Buy | Get Alert | |
| Mar 13, 2025 | 1318.92% | 2121 | Previous Buy Current Buy | Get Alert | |
| Aug 20, 2024 | 1318.92% | 2121 | Previous Buy Current Buy | Get Alert | |
| Jun 28, 2024 | 1318.92% | 2121 | Previous Buy Current Buy | Get Alert | |
| Feb 14, 2024 | 1318.92% | 2121 | Previous Buy Current Buy | Get Alert | |
| Nov 29, 2023 | 1318.92% | 2170 | Previous Buy Current Buy | Get Alert | |
| Nov 22, 2023 | 575.68% | 10 | Previous Buy Current Buy | Get Alert | |
| Oct 12, 2023 | 3751.35% | 57 | Previous Buy Current Buy | Get Alert | |
| Aug 15, 2023 | 575.68% | 1016 | Previous Buy Current Buy | Get Alert | |
| May 24, 2023 | 981.08% | 16 | Previous Buy Current Buy | Get Alert | |
| Mar 15, 2023 | 981.08% | 16 | Previous Current Buy | Get Alert | |
| Feb 14, 2023 | 981.08% | 16 | Previous Current Buy | Get Alert |
The latest price target for Edesa Biotech (NASDAQ:EDSA) was reported by HC Wainwright & Co. on November 3, 2025. The analyst firm set a price target for $5.00 expecting EDSA to rise to within 12 months (a possible 237.84% upside). 3 analyst firms have reported ratings in the last year.
The latest analyst rating for Edesa Biotech (NASDAQ:EDSA) was provided by HC Wainwright & Co., and Edesa Biotech reiterated their buy rating.
There is no last upgrade for Edesa Biotech
There is no last downgrade for Edesa Biotech.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Edesa Biotech, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Edesa Biotech was filed on November 3, 2025 so you should expect the next rating to be made available sometime around November 3, 2026.
While ratings are subjective and will change, the latest Edesa Biotech (EDSA) rating was a reiterated with a price target of $5.00 to $5.00. The current price Edesa Biotech (EDSA) is trading at is $1.48, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.